Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;34(2):378-395.
doi: 10.1007/s12325-016-0461-z. Epub 2016 Dec 20.

Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma

Vanessa Andrés-Guerrero  1   2   3 , Lucía Perucho-González  1   2   3 , Julián García-Feijoo  1   2   3 , Laura Morales-Fernández  1   2   3 , Federico Saenz-Francés  1   2   3 , Rocío Herrero-Vanrell  1   4   3 , Luis Pablo Júlvez  1   5   6 , Vicente Polo Llorens  1   5   6 , José María Martínez-de-la-Casa  1   2   3 , Anastasios-Georgios Konstas  7
Affiliations
Review

Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma

Vanessa Andrés-Guerrero et al. Adv Ther. 2017 Feb.

Abstract

The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.

Keywords: Aflibercept; Angiogenesis; Bevacizumab; Glaucoma filtration surgery; Neovascular glaucoma; Ranibizumab; VEGF; Wound modulation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Anti-vascular endothelial growth factor drugs for ocular diseases
See this image and copyright information in PMC

References

    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267. doi: 10.1136/bjo.2005.081224. - DOI - PMC - PubMed
    1. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Italy: PubliComm; 2014.
    1. Salim S. Current variations of glaucoma filtration surgery. Curr Opin Ophthalmol. 2012;23(2):89–95. doi: 10.1097/ICU.0b013e32834ff401. - DOI - PubMed
    1. Yu DY, Morgan WH, Sun X, et al. The critical role of the conjunctiva in glaucoma filtration surgery. Prog Retin Eye Res. 2009;28(5):303–328. doi: 10.1016/j.preteyeres.2009.06.004. - DOI - PubMed
    1. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48(3):314–346. doi: 10.1016/S0039-6257(03)00038-9. - DOI - PubMed

MeSH terms